Veracyte Yönetim

Yönetim kriter kontrolleri 3/4

Veracyte CEO'su Marc Stapley, Jun2021 tarihinde atandı, in görev süresi 3.42 yıldır. in toplam yıllık tazminatı $ 7.18M olup, şirket hissesi ve opsiyonları dahil olmak üzere 9% maaş ve 91% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.16% ine doğrudan sahiptir ve bu hisseler $ 4.28M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 3.7 yıldır.

Anahtar bilgiler

Marc Stapley

İcra Kurulu Başkanı

US$7.2m

Toplam tazminat

CEO maaş yüzdesi	9.0%
CEO görev süresi	3.4yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	3.7yrs

Son yönetim güncellemeleri

Recent updates

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 42%

Aug 18

Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 09

Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price

Jul 02

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking

Jun 06

Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 09

Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

Apr 18

A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Mar 18

Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk

Jul 13

Veracyte: Not A Healthy Diagnosis

May 12

CEO Tazminat Analizi

Marc Stapley'un ücretlendirmesi Veracyte'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$54m
Mar 31 2024	n/a	n/a	-US$68m
Dec 31 2023	US$7m	US$650k	-US$74m
Sep 30 2023	n/a	n/a	-US$50m
Jun 30 2023	n/a	n/a	-US$29m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	US$5m	US$625k	-US$37m
Sep 30 2022	n/a	n/a	-US$43m
Jun 30 2022	n/a	n/a	-US$49m
Mar 31 2022	n/a	n/a	-US$48m
Dec 31 2021	US$6m	US$350k	-US$76m

Tazminat ve Piyasa: Marc 'ın toplam tazminatı ($USD 7.18M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 6.65M ).

Tazminat ve Kazançlar: Marc şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Marc Stapley (54 yo)

3.4yrs

Görev süresi

US$7,184,634

Tazminat

Mr. Marc A. Stapley serves as Chief Executive Officer at Veracyte, Inc. since June 1, 2021 and serves as its Director since June 08, 2021. He served as the Chief Executive Officer of Helix OpCo, LLC from A...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Marc Stapley	CEO & Director	3.4yrs	US$7.18m	0.16% $ 4.3m
Rebecca Chambers	Executive VP & CFO	3.3yrs	US$2.78m	0.047% $ 1.2m
Phillip Febbo	Chief Scientific & Medical Officer	1.1yrs	US$4.20m	Veri yok
Annie McGuire	Executive VP	2.8yrs	US$2.48m	0.022% $ 577.7k
John Leite	Chief Commercial Officer for CLIA Business	2.2yrs	US$2.77m	0.0047% $ 123.3k
Jonathan Wygant	VP & Chief Accounting Officer	2.8yrs	Veri yok	0.014% $ 360.5k
Steven French	Senior VP & Chief Information Officer	2.8yrs	Veri yok	Veri yok
Karen Possemato	Senior Vice President of Corporate Marketing	less than a year	Veri yok	Veri yok
Robert Brainin	Executive VP & Chief Business Officer	3.3yrs	Veri yok	Veri yok
Corinne Danan	Senior Vice President	1.6yrs	Veri yok	Veri yok
Beverly Alley	VP & Corporate Controller	3.8yrs	US$1.29m	Veri yok
Shayla Gorman	Director of Investor Relations	no data	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: VCYT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Marc Stapley	CEO & Director	3.4yrs	US$7.18m	0.16% $ 4.3m
Karin Eastham	Independent Director	11.9yrs	US$314.98k	0.028% $ 746.4k
Evan Jones	Independent Director	16.8yrs	US$314.98k	0.030% $ 784.6k
Robert Epstein	Independent Chair	9.8yrs	US$337.98k	0.043% $ 1.1m
Jens Holstein	Independent Director	4.3yrs	US$327.47k	0.021% $ 562.9k
David Shafer	Director	less than a year	Veri yok	Veri yok
Edison Liu	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Muna Bhanji	Independent Director	3.7yrs	US$299.98k	0.030% $ 790.4k
Thomas Miller	Director	less than a year	Veri yok	Veri yok
Eliav Barr	Independent Director	2.3yrs	US$294.98k	0.022% $ 569.0k

3.7yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: VCYT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.7 yıldır).

Veracyte Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Veracyte, Inc. Announces New Board Appointments

Veracyte, Inc., Annual General Meeting, Jun 12, 2024

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors

Veracyte, Inc. Appoints Phillip G. Febbo as Chief Scientific Officer and Chief Medical Officer, Effective 2, 2023

Recent updates

Veracyte, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Veracyte, Inc. Presented New Data At Astro 2024 Show That Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men

Veracyte, Inc. Announces New Data from a Phase 3 Trial of the Multi-Center, Randomized Stampede Clinical Trial

Veracyte, Inc. Announces New Board Appointments

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 42%

Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2024

Veracyte, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking

Veracyte, Inc. Announces New Afirma Grid Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

Consensus EPS estimates upgraded to US$0.052 loss

New major risk - Revenue and earnings growth

Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2024

Veracyte, Inc., Annual General Meeting, Jun 12, 2024

Veracyte, Inc. to Report Q1, 2024 Results on May 07, 2024

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

New minor risk - Shareholder dilution

New minor risk - Profitability

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Veracyte, Inc. Provides Earnings Guidance for the Full Year 2024

Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors

Veracyte, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Veracyte, Inc. (NasdaqGM:VCYT) completed the acquisition of C2i Genomics, Inc.

Veracyte, Inc. (NasdaqGM:VCYT) has reached a definitive agreement to acquire C2i Genomics, Inc. for $95 million.

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

Veracyte, Inc. Reports Consolidated Impairment Charges for the Quarter Ended September 30, 2023

Veracyte, Inc. Raises Revenue Guidance for the Full Year 2023

Veracyte, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Veracyte, Inc. Announces New Data from A Large, Randomized Phase 3 Trial Reinforce the Value of the Decipher Prostate Genomic Classifier in Helping Physicians Make More Informed Treatment Decisions for Their Patients with Prostate Cancer

Veracyte, Inc. Announces New Data Presented At the 2023 American Thyroid Association Annual Meeting Demonstrate That Veracyte's Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer

Veracyte, Inc. Appoints Phillip G. Febbo as Chief Scientific Officer and Chief Medical Officer, Effective 2, 2023

Veracyte, Inc. Announces Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer

Consensus estimates of losses per share improve by 11%

Veracyte, Inc. Announces Resignation of Tina S. Nova as General Manager, Urological Cancers Effective September 4, 2023

Veracyte, Inc. Revises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Veracyte, Inc. Announces New Data Suggest Veracyte's Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer

Independent Director notifies of intention to sell stock

Veracyte Announces That New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer

Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

Co-Founder & Executive Chairwoman notifies of intention to sell stock

Co-Founder & Executive Chairwoman notifies of intention to sell stock

A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Independent Director notifies of intention to sell stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. Announces New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment

Veracyte, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Co-Founder & Executive Chairwoman exercised options and sold US$682k worth of stock

Veracyte, Inc. Announces Resignation of Giulia C. Kennedy as Global Chief Scientific Officer and Chief Medical Officer

Co-Founder & Executive Chairwoman exercised options and sold US$1.4m worth of stock

Independent Director recently sold US$181k worth of stock

Consensus estimates of losses per share improve by 28%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. Raises Revenue Guidance for the Year 2022

Veracyte, Inc. Announces New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy

Veracyte, Inc. Announces Data That Provide New Insights into Thyroid Tumor Behavior

New Data Presented At American College of Chest Physicians 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

Co-Founder & Executive Chairwoman exercised options to buy US$188k worth of stock.

Veracyte, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Veracyte, Inc. Publishes New Data in JNCI Demonstrate its Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men